我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

高密度脂蛋白与心血管保护的研究进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第1期
页码:
120-122
栏目:
综述
出版日期:
2012-02-25

文章信息/Info

Title:
Recent advance on high-density lipoprotein and its protection of cardiovascular disease
作者:
路英杰; 杨 雪; 张旭昌 综述; 王晓云 审校
(哈尔滨医科大学附属四院心内科一病房，黑龙江 哈尔滨 150001)
Author(s):
LU Ying-jie;  YANG Xue;  ZHANG Xu-chang;  WANG Xiao-yun
（First Ward, Department of Cardiology, Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China）
关键词:
高密度脂蛋白; 心血管保护; 冠状动脉疾病
Keywords:
high-density lipoprotein (HDL);  Cardiovascular protection; Coronary artery disease
分类号:
Q513.5
DOI:
-
文献标识码:
A
摘要:
多项大规模临床研究显示，血清高密度脂蛋白（HDL）的水平与冠心病存在着密切的联系。HDL胆固醇对心血管的保护作用，体现在可介导胆固醇逆向转运、抗氧化作用、调节内皮功能、抗炎及影响凝血系统等。本文对HDL的结构和代谢进行了回顾，并对其心血管保护作用的新进展进行了综述。
Abstract:
Many large-scale clinical studies show that high-density lipoprotein (HDL) level is closely related to coronary heart disease. Its cardiovascular protection is reflected in reversing cholesterol transport, anti-oxidation, adjusting endothelial function, anti-inflammatory, and exhibiting multiple beneficial effects on the coagulation system. In this paper, the structure and the metabolism of HDL as well as the progress on its protection of cardiovascular disease were reviewed.

参考文献/References

[1]Wasan KM,Brocks DR,Lee SD,et al.Impact of lipoproteins on the biological and disposition of hydropholic drugs: implications for drugs discovery[J].Nat Rev Drug Dicov,2008,7(1):84-89.

[2]Lee MH,Hammad SM,Semler AJ,et al.HDL3,but not HDL2,stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate[J].Lipid Res,2010,51(9):2619-2628.

[3]Toth PP.Torcetrapib and atherosclerosis:what happened and where do we go from here?[J].Future Lipidol,2007,2:227-284.

[4]常冠楠,徐 新,张社兵.B类Ⅰ型清道夫受体的研究进展[J].中西医结合心脑血管病杂志,2010,8(9):1126-1129

[5]Navab M,Reddy ST,Van Lenten BJ,et al.The role of dysfunctional HDL in atherosclerosis[J].J Lipid Res,2009,50(Suppl):S145-S149.

[6]Tolle M,Pawlak A,Schuchardt M,et al.HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production[J].Arterioscler Thromb Vasc Biol,2008,28(8):1542-1548.

[7]Tamehiro N,Shigemoto-Mogami Y,Kakeya T,et al.Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism under-lying the unique response to cellular cholesterol status[J].Biol Chem,2007,282(29):21090-21099.

[8]Nissen SE,Tardif JC,Nicholls SJ,et al.Effect of torcetrapib on the progression of coronary atherosclerosis[J].N Engl J Med,2007,356(13):1304-1316．

[9]Kastelein JJ,van Leuven SI, Burgess L,et al.Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia[J].N Engl J Med, 2007, 356(16):1620-1630.

[10]Bots ML,Visseren FL,Evans GW,et al.Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study):a randomised,double-blind trial[J].Lancet,2007,370(9582):153-160.

[11]Bloomfield D,Carlson GL,Sapre A,et al.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients[J].Am Heart J,2009,157(2):352-360.

[12]Tardif JC,Grégoire J,Heinonen TM,et al.Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial[J]. JAMA,2007,297(15):1675-1682.

[13]Tabet F,Remaley AT,Segaliny AI,et al.The 5A Apolipoprotein A-I Mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro[J].Arterioscler Thromb Vasc Biol,2010,30(2):246-252.

备注/Memo

备注/Memo:
收稿日期：2011-06-30.通讯作者：王晓云，主任，主要从事冠心病介入治疗研究 Email：wxy@medmail.com.cn 作者简介：路英杰，硕士生 Email:yuequanxiaoming2008@126.com
更新日期/Last Update: 2012-02-14